ABC News - Fri, Apr 12, 2013After battling breast cancer in 2008, Lisbeth Ceriani took on a whole new challenge. She joined a lawsuit against a biotechnology company she believed was blocking her ability to make informed decisions about her ongoing treatment.Myriad Genetics was awarded patents in the 1990s on two isolated genes called BRCA 1 and BRCA2 as well as diagnostic methods. Women with mutations in those genes are at a much higher risk for breast and ovarian cancer. Because of the patent, Myriad is the only place to go for testing, and it sets the $3,340 price tag. ... More »Can You Patent Human Genes?